An interventional study of Spiroergometer test with intranasal insulin spray and Spiroergometer test with intranasal placebo spray in Insulin Sensitivity, sponsored by University of Ulm. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Ulm · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Insulin Resistance with a site in Germany — 17 open to participants now, 20 under way, none of them phase 3. Insulin Resistance · Germany.
Among the 92 studies in Insulin Resistance with a site in Germany, this one is the 75th largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2026, is one of 44 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 91st registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →17 of the 92 studies in Insulin Resistance with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–79
University of Bonn · Sites in Germany
Ages 18–60 · Healthy volunteers
University of Ulm · Sites in Germany
Ages 18+ · Healthy volunteers
University Hospital Tuebingen · Sites in Germany
Ages 18–70 · Healthy volunteers
German Diabetes Center · Sites in Germany
Ages 18–40 · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 12 · Phase 3 6 · Phase 4 7
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 37 across the 78 interventional studies, 475 across the 14 observational. Of the 65 that completed or were terminated, 10 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 92 have an industry lead sponsor. The 10 most frequent:
University of Ulm is the lead sponsor of 145 studies on the registry; 27 are open to participants now.
University of Ulm has 4 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
6 of the studies in Insulin Resistance with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06039787University Hospital TuebingenExercise Training on Brain Insulin Responsiveness | 2026-12-31 |
| NCT06982859Eli Lilly and CompanyA Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | 2027-01 |
| NCT06912048University of UlmUnderstanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease | 2027-04 |
| NCT04270578University Hospital TuebingenGestational Diabetes | 2027-05-01 |
| NCT07466173University of UlmThe Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 92 studies in Insulin Resistance with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to clarify the interaction of central insulin action and physical activity with the immune system. Therefore, participants will undergo bicycle spiroergometer tests. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray. In another trial (NCT06552130) lean participants already have been tested. Significant effects on circulating cytokines could be identified. In this amendment, overweight persons in which brain insulin resistance is expected will be tested.
This research project aims to investigate if the brain insulin action regulates the immune system via the autonomous nervous system during physical activity and investigate whether participants with overweight respond different compared to lean persons. The lean persons were already studied in another trial (NCT06552130) and this trial serves as an amendment.
Insulin action in the brain will be introduced by application of insulin as nasal spray (on one day) versus carrier solution as placebo nasal spray (on another day) in a randomized, blinded fashion. Spray administration will be performed 30 minutes before a 60 min bicycle spiroergometer test at 70 % VO2max that will introduce a postprandial state. On placebo day, the known spillover of tiny amounts of nasal insulin into the systemic circulation will be mimicked by an appropriate i.v. insulin bolus. Using this approach, brain-derived regulation of the immune system including the stimulation of immune cells via cytokines, physical performance, activity of the autonomous nervous system and gene-expression of leukocytes will be examined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 Units of human insulin as nasal spray
Other: Spiroergometer test with intranasal insulin spray
Nasal spray containing placebo solution
Other: Spiroergometer test with intranasal placebo spray
Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
Immune system activation
Influence of central nervous insulin action on the activation of the immune system activation by exercise, measured by circulating cytokines and cytokines in the supernatant of stimulated peripheral blood mononuclear cells.
Time frame: 120 minutes
Maximal oxygen consumption (VO2max)
Influence of central nervous insulin action on physical performance measured as VO2 peak during spiroergometry.
Time frame: 60 minutes
Heat rate variability
Influence of central nervous insulin action on the activity of the autonomic nervous system recorded by means of heart rate variability from an electrocardiogram.
Time frame: 120 minutes
Corticotropic pituitary axis modulation
Corticotropic pituitary axis modulation Influence of central nervous insulin action in the activity of the corticotropin pituitary axis during physical activity, measured by cortisol, dehydroepiandrosterone and adrenocorticotropic hormone
Time frame: 120 minutes
Leukocyte gene expression
Influence of central nervous insulin action on the gene expression of leukocytes during physical activity
Time frame: 120 minutes
Individual anaerobic threshold
Influence of central nervous insulin action on physical performance. Individual anaerobic threshold assessed by lactate measurement from venous blood sampling.
Time frame: 120 minutes
Catecholamines
Influence of central nervous insulin action on the activity of the autonomic nervous system recorded by means of measuring catecholamine concentrations from venous blood.
Time frame: 120 minutes
Effects on blood coagulation parameters
Influence of central nervous insulin action and/or physical activity on blood coagulation parameters assessed through global coagulation tests and single coagulation factors.
Time frame: 120 minutes
Sex differences
Potential differences in the above mentioned outcomes between sexes will be analyzed.
Time frame: 120 minutes
Differences between lean and overweight persons
Potential differences in the above mentioned outcomes between lean individuals studied in (NCT06552130) and overweight individuals studied in this trial.
Time frame: 120 minutes
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jun 2027, 7 months after the start.
Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.
Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Apr 2026 → Nov 2026, primary completion Dec 2026 → Jun 2027 and completion Jun 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.